Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mingwu Zheng

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
IEEE Transactions on Pattern Analysis and Machine Intelligence|October 14, 2024
ImFace++: A Sophisticated Nonlinear 3D Morphable Face Model With Implicit Neural RepresentationsMingwu Zheng, Haiyu Zhang, Hongyu Yang, et al.
Molecular Cancer Therapeutics|December 19, 2014
A preclinical evaluation of SKLB261, a multikinase inhibitor of EGFR/Src/VEGFR2, as a therapeutic agent against pancreatic cancerYouli Pan, Mingwu Zheng, Lei Zhong, et al.
Oncotarget|January 18, 2018
A novel orally available Syk/Src/Jak2 inhibitor, SKLB-850, showed potent anti-tumor activities in B cell lymphoma (BCL) modelsNannan Zhang, Guo Zhang, Ning Liu, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
IEEE Transactions on Pattern Analysis and Machine Intelligence|October 14, 2024
ImFace++: A Sophisticated Nonlinear 3D Morphable Face Model With Implicit Neural RepresentationsMingwu Zheng, Haiyu Zhang, Hongyu Yang, et al.
Molecular Cancer Therapeutics|December 19, 2014
A preclinical evaluation of SKLB261, a multikinase inhibitor of EGFR/Src/VEGFR2, as a therapeutic agent against pancreatic cancerYouli Pan, Mingwu Zheng, Lei Zhong, et al.
Oncotarget|January 18, 2018
A novel orally available Syk/Src/Jak2 inhibitor, SKLB-850, showed potent anti-tumor activities in B cell lymphoma (BCL) modelsNannan Zhang, Guo Zhang, Ning Liu, et al.
Pageof 1